[1]董立红,张大传.不同时机视网膜激光光凝辅助康柏西普治疗视网膜中央静脉阻塞继发黄斑水肿的疗效分析[J].眼科新进展,2022,42(7):546-550.[doi:10.13389/j.cnki.rao.2022.0112]
　DONG Lihong,ZHANG Dachuan.Clinical effect of retinal photocoagulation and conbercept in the treatment of macular edema secondary to central retinal vein occlusion at different times[J].Recent Advances in Ophthalmology,2022,42(7):546-550.[doi:10.13389/j.cnki.rao.2022.0112]
点击复制

不同时机视网膜激光光凝辅助康柏西普治疗视网膜中央静脉阻塞继发黄斑水肿的疗效分析/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年7期
页码:
546-550
栏目:
应用研究
出版日期:
2022-07-05

文章信息/Info

Title:
Clinical effect of retinal photocoagulation and conbercept in the treatment of macular edema secondary to central retinal vein occlusion at different times
作者:
董立红; 张大传
238000　安徽省巢湖市，安徽医科大学附属巢湖医院眼科（董立红）；230000　安徽省合肥市，安徽省合肥市第三人民医院眼科（张大传）
Author(s):
DONG Lihong1;  ZHANG Dachuan2
1.Department of Ophthalmology, Chaohu Hospital of Anhui Medical University, Chaohu 238000, Anhui Province, China
2.Department of Ophthalmology, the Third People’s Hospital of Hefei, Hefei 230000, Anhui Province, China
关键词:
视网膜中央静脉阻塞; 黄斑水肿; 激光光凝; 康柏西普
Keywords:
central retinal vein occlusion;  macular edema;  laser photocoagulation;  conbercept
分类号:
R774
DOI:
10.13389/j.cnki.rao.2022.0112
文献标志码:
A
摘要:
目的　分析不同时机的视网膜激光光凝辅助康柏西普治疗对视网膜中央静脉阻塞（CRVO）继发黄斑水肿（ME）患者疗效的影响。方法　收集2017年6月至2019年6月于安徽医科大学附属巢湖医院眼科收治的101例（101眼）CRVO继发ME患者，按治疗情况分药物组（康柏西普治疗）、联合组A（康柏西普联合激光光凝治疗，病程<3个月）、联合组B（康柏西普联合激光光凝治疗，病程≥3个月），3组患者均按每月1次的频率接受3次玻璃体内注射康柏西普治疗，3次后接受按需治疗；联合组A、联合组B则在每次药物注射3 d后接受激光光凝治疗；比较3组患者康柏西普注射次数、视力、黄斑中心凹视网膜厚度（CMT）、视网膜出血吸收情况、无灌注区消退及新生血管情况。结果　联合组A、联合组B患者康柏西普平均注射次数均显著低于药物组，但联合组A与联合组B患者间比较差异无统计学意义（P>0.05）；联合组A、联合组B患者视力变化均优于药物组（均为P<0.001），且联合组A患者视力提高比例优于联合组B（P=0.027）；联合组A、联合组B患者治疗后1个月、3个月、6个月、12个月时的CMT均显著高于药物组（均为P<0.05），但联合组A与联合组B患者间各时间点CMT相比差异均无统计学意义（均为P>0.05）；联合组A、联合组B患者出血吸收情况及基于无灌区和新生血管情况的疗效等级均优于药物组（均为P<0.001），且联合组A患者的出血吸收情况及疗效等级均优于联合组B（均为P<0.05）。结论　CRVO继发ME患者早期开展激光光凝治疗可获得更好的视力改善，出血吸收、无灌注区消退效果更佳，在抑制新生血管形成上优势更显著。
Abstract:
Objective　To analyze the clinical effect of retinal photocoagulation and conbercept in the treatment of macular edema (ME) secondary to central retinal vein occlusion (CRVO) at different times. Methods　A total of 101 patients (101 eyes) with ME secondary to CRVO admitted to the Department of Ophthalmology, the Third People’s Hospital of Hefei, Anhui Province from June 2017 to June 2019 were enrolled and divided into the drug group (conbercept), combined group A (conbercept and laser photocoagulation, course of the disease <3 months), and combined group B (conbercept and laser photocoagulation, course of the disease ≥3 months) according to the treatment. All patients were intravitreally injected with conbercept once a month for three months, and three months later, they were treated as needed. Patients in the combined groups A and B received laser photocoagulation on day 3 after each injection of conbercept. The number of conbercept injections, visual acuity, central macular thickness (CMT), absorption of retinal bleeding, regression in non-perfusion area (NPA), and neovascularization were compared among the three groups. Results　The mean number of conbercept injections in the combined groups A and B was significantly less than that in the drug group, but there was no statistically significant difference between the combined groups A and B (P>0.05). The visual acuity of patients in the combined groups A and B was better than that in the drug group (P<0.001), and the visual acuity in the combined group A was better than that in the combined group B (P=0.027). CMT at 1 month, 3 months, 6 months and 12 months after treatment in the combined groups A and B was significantly higher than that in the drug group (all P<0.05), but there was no statistically significant difference between the combined groups A and B (all P>0.05). Bleeding absorption and curative effects based on NPA and neovascularization in the combined groups A and B were better than those in the drug group (all P<0.001). Bleeding absorption and curative effects based on NPA and neovascularization in the combined group A were better than those in the combined group B (all P<0.05). Conclusion　Early laser photocoagulation can better improve visual acuity, bleeding absorption and NPA regression in patients with ME secondary to CRVO. It has more advantages in inhibiting neovascularization.

参考文献/References:

［1］　BROGAN K,PRECUP M,RODGER A,YOUNG D,GILMOUR D F.Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab［J］.BMC Ophthalmol,2018,18(1):37.
［2］　EHSAN R R,BRADY J C.Treat-and-extend regimen for macular edema secondary to central retinal vein occlusion:12-month results［J］.Ophthalmol Retina,2017,1(2):118-123.
［3］　CHATZIRALLI I,THEODOSSIADIS G,MOSCHOS M M,MITROPOULOS P,THEODOSSIADIS P.Ranibizumab vs.Aflibercept for macular edema due to central retinal vein occlusion［J］.Ophthalmol Retina,2019,1(4):355-356.
［4］　浦利军,承伟,顾晖晖,牟朝霞.不同激光光凝治疗时机联合玻璃体注射康柏西普治疗视网膜中央静脉阻塞继发黄斑水肿的有效性及安全性［J］.中国老年学杂志,2020,40(10):2124-2127.
PU L J,CHENG W,GU H H,MOU C X.Efficacy and safety of different timing of laser photocoagulation combined with vitreous injection of Conbercept in the treatment of macular edema secondary to central retinal vein occlusion ［J］.Chin J Gerontol,2020,40(10):2124-2127.
［5］　刘隽,杨晓春,梅妍,雷霍,赵海燕.康柏西普玻璃体内注射联合黄斑格栅样激光光凝治疗非缺血性视网膜分支静脉阻塞继发黄斑水肿的疗效观察［J］.中华眼底病杂志,2017,33(2):119-123.
LIU J,YANG X C,MEI Y,LEI H,ZHAO H Y.Intravitreal injection of conbercept combined with macular grid laser photocoagulation in the treatment of macular edema secondary to non ischemic branch retinal vein occlusion［J］.Chin J Ocul Fundus Dis,2017,33(2):119-123.
［6］　李凤鸣.中华眼科学［M］.北京:人民卫生出版社,2005:119-120.
LI F M.Chinese ophthalmology［M］.Beijing:People’s Health Publishing House,2005:119-120.
［7］　张伟,毕大光,谷树严.视网膜静脉阻塞激光光凝的时机选择［J］.国际眼科杂志,2014,14(8):1403-1406.
ZHANG W,BI D G,GU S Y.Timing of retinal vein occlusion laser photocoagulation［J］.Int Eye Sci,2014,14(8):1403-1406.
［8］　王海燕,王雨生.再度审视激光光凝在视网膜血管疾病治疗中的价值［J］.中华眼底病杂志,2018,34(5):424-428.
WANG H Y,WANG Y S.A new insight of the value of laser photocoagulation on retinal vascular diseases［J］.Chin J Ocul Fund Dis,2018,34(5):424-428.
［9］　BERGER A R,CRUESS A F,ALTOMARE F,CHAUDHARY V,COLLEAUX K,GREVE M,et al.Optimal treatment of retinal vein occlusion:Canadian expert consensus［J］.Ophthalmologica,2015,234(1):6-25.
［10］　REHAK M,TILGNER E,FRANKE A,RAUSCHER F G,BROSTEANU O,WIEDEMANN P.Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (results of a proof of concept study)［J］.Graefes Arch Clin Exp Ophthalmol,2014,252(5):745-752.
［11］　BROWN D M,NGUYEN Q D,MARCUS D M,BOYER D S,PATEL S,FEINER L,et al.Long-term outcomes of ranibizumab therapy for diabetic macular edema:the 36-month results from two phase III trials:RISE and RIDE［J］.Ophthalmology,2013,120(10):2013-2022.
［12］　李仕永,高瑞莹,陈晖.雷珠单抗联合氩激光视网膜光凝治疗不同时期的视网膜分支静脉阻塞所致黄斑水肿的疗效［J］.眼科新进展,2016,36(12):1161-1164.
LI S Y,GAO R Y,CHEN H.Effects of ranibizumab (Lucentis) intravitreal injection combined with retinal Argon laser photocoagulation on macular edema secondary to different period of branch retinal vein occlusion［J］.Rec Adv Ophthalmol,2016,36(12):1161-1164.
［13］　WAI K M,KHAN M,SRIVASTAVA S,RACHITSKAYA A,SILVA F Q,DEASY R,et al.Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice［J］.Br J Ophthalmol,2017,101(5):574-579.
［14］　SZURMAN G B,Bevacizumab Study Group Venous Occlusion,CARSTEN H M,FELTGEN N,PIELEN A,BERNHARD S,et al.Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion［J］.Graefes Arch Clin Exp Ophthalmol,2017,255(5):1045-1046.
［15］　Branch Vein Occlusion Study Group.Argon laser photocoagulation for macular edema in branch vein occlusion［J］.Am J Ophthalmol,2018,196(27):xxx-xxxviii.
［16］　LIP P L,CIKATRICIS P,SARMAD A,DAMATO E M,CHAVAN R,MITRA A,et al.Efficacy and timing of adjunctive therapy in the anti-VEGF treatment regimen for macular oedema in retinal vein occlusion:12-month real-world result［J］.Eye (Lond),2018,32(3):537-545.
［17］　BITIRGEN G,BELVIRANLI S,MALIK R A,KERIMOGLU H,OZKAGNICI A.Effects of panretinal laser photocoagulation on the corneal nerve plexus and retinal nerve fiber layer in retinal vein occlusion［J］.Eur J Ophthalmol,2017,27(5):591-595.

相似文献/References:

[1]杨于力 刘勇 阴正勤 王一.眼部缺血综合征患者视网膜电图明视负向反应和震荡电位的变化特点[J].眼科新进展,2012,32(4):000.
[2]李国兴 韩丽英.曲安奈德玻璃体腔注射治疗黄斑水肿[J].眼科新进展,2008,28(9):000.
[3]周正申 孙静芬.白内障超声乳化术后黄斑区光学相干断层扫描观察[J].眼科新进展,2013,33(2):000.
[4]刘广峰 蔺洁 范颖 顾铮 高新晓 朱岩 孟忻 王华 贾宇颂 付秀稳 汪军.非增生型糖尿病视网膜病变黄斑水肿患者黄斑区谱域光学相干断层扫描中高反射信号的特征分析[J].眼科新进展,2013,33(4):000.
[5]鲁丹 王康 王艳玲 林鹏耀 李茜 李明铭.后Tenon囊下注射曲安奈德辅助全视网膜光凝治疗糖尿病视网膜病变[J].眼科新进展,2013,33(5):000.
[6]魏光杰 何佃菊.532nm绿激光全视网膜光凝术联合中药治疗视网膜中央静脉阻塞的疗效分析[J].眼科新进展,2013,33(10):000.
[7]刘李平 宋徽 肖云 曹小鹏 白润 陈珍.玻璃体注射雷珠单抗治疗缺血型视网膜中央静脉阻塞的临床观察[J].眼科新进展,2013,33(11):000.
[8]张祺 冯劼 李培凤 金翼.Lucentis联合氪黄激光治疗视网膜分支静脉阻塞黄斑水肿的疗效观察[J].眼科新进展,2013,33(12):000.
[9]陆秉文 吴星伟.视网膜静脉阻塞黄斑水肿患者玻璃体内注射ranibi-zumab后视野变化[J].眼科新进展,2013,33(12):000.
[10]徐斌 戴奕娟 梁丽 杨露. 传统格栅样激光与577nm黄色微脉冲激光光凝治疗黄斑水肿疗效对比[J].眼科新进展,2014,34(2):181.
[11]王梅子,封康,陆遥,等.贝伐单抗治疗视网膜中央静脉阻塞（CRVO）继发黄斑水肿的短期疗效及影响因素分析[J].眼科新进展,2018,38(12):1176.[doi:10.13389/j.cnki.rao.2018.0278]
　WANG Mei-Zi,FENG Kang,LU Yao,et al.Analysis of short-term outcomes and factors for intravitreal bevacizumab in the treatment of macular edema secondary to central retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(7):1176.[doi:10.13389/j.cnki.rao.2018.0278]
[12]赵通,张利,尹玥,等.玻璃体内注射康柏西普联合后筋膜囊注射曲安奈德对视网膜中央静脉阻塞继发顽固性黄斑水肿患者的治疗效果[J].眼科新进展,2020,40(4):369.[doi:10.13389/j.cnki.rao.2020.0085]
　ZHAO Tong,ZHANG Li,YIN Yue,et al.Efficacy of intravitreal injection of Conbercept combined with posterior fascial capsular injection of Triamcinolone Acetonide for treatment of macular edema secondary to central retinal vein occlusion[J].Recent Advances in Ophthalmology,2020,40(7):369.[doi:10.13389/j.cnki.rao.2020.0085]

更新日期/Last Update: 2022-07-05